Pfizer Inc.’s next-generation treatment for breast cancer posted mixed results in a final-stage study, a potential setback ...

A Brooklyn brownstone with a long history starting with the Pfizer family has hit the market for $10.35 million—after setting ...

and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial NEW ...

Pfizer (PFE) stock gains as company appoints James List, a former J&J (JNJ) executive as Chief Internal Medicine Officer to ...

Pfizer Supercharges Obesity Battle with Top J&J Exec ...

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

STORY HIGHLIGHTS Lightstone Group purchased two industrial buildings in Triangle area. Lightstone sees strategic investment opportunities in the Triangle region. Other NY firms also investing in North ...

the president wanting tax cuts in the reconciliation bill and the New York special election. The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.